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A B S T R A C T   
Purpose: For a successful bronchoscopic lung volume reduction coil treatment it is important to place the coils in 
the most emphysematous lobes. Therefore assessment of the lobe with greatest destruction is essential. Our aims 
were to investigate the level of agreement among expert reviewers of HRCT-scans in emphysema patients and the 
comparison with QCT (quantitative computed tomography) software. 
Method: Five experienced CT-assessors, conducted a visual assessment of the baseline HRCT-scans of emphysema 
patients who participated in the RENEW bronchoscopic lung volume reduction coil study. On the same HRCT- 
scans, a QCT analysis was performed. 
Results: In total 134 HRCT-scans were rated by all 5 experts. All 5 CT-assessors agreed on which was the most 
destructed lobe in 61 % of the left lungs (ƙ:0.459) and 60 % of the right lungs (ƙ:0.370). The consensus of the 5 
assessors matched the QCT in the left lung for 77 % of the patients (ƙ:0.425) and in the right lung for 82 % 
(ƙ:0.524). 
Conclusions: Our results show that the interobserver agreement between five expert CT-assessors was only fair to 
moderate when evaluating the most destructed lobe. CT-assessor consensus improved matching with QCT 
determination of lobar destruction compared to individual assessor determinations. Because some CT-features 
are associated with treatment outcomes and important for optimal patient selection of bronchoscopic lung 
volume reduction treatment, we recommend including more than one CT-reviewer and supported by QCT 
measurements.   
1. Introduction 
Computed tomography of the chest (CT scans) are important in pa-
tient selection for bronchoscopic lung volume reduction treatments, like 
the endobronchial valve or lung volume reduction coil treatment in 
Chronic Obstructive Pulmonary Disease (COPD) patients with emphy-
sema [1,2]. CT features that are important include: interlobar fissure 
completeness, the degree and distribution of emphysematous destruc-
tion on a lobar level, and the presence of significant co-morbidity or 
abnormalities [2]. Quantitative assessment of CT-scans (QCT) by (semi-) 
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automatic software is an important supportive tool. For bronchoscopic 
lung volume reduction with endobronchial valves, QCT is already 
incorporated in patient selection as it has proven additional value for the 
evaluation of fissure completeness [3,4]. 
Completeness of the target lobe fissure is not a prerequisite for 
bronchoscopic lung volume reduction treatment using coils. However, 
according to an expert panel recommendation, the coils should be 
placed in the lobe with the greatest degree of emphysematous destruc-
tion per lung in order to achieve optimal treatment outcome [5]. The 
RENEW-study, a large multicenter randomized controlled trial investi-
gating the coil treatment, relied on a visual CT-analysis by the pulmo-
nologist without support of QCT to select the most destructed lobes for 
treatment [6,7] A recent post-hoc analysis of the RENEW-study showed 
that 38 % of patients received one or both coil treatments in the ipsi-
lateral lobe of lesser emphysematous destruction according to the 
QCT-analysis [7]. These patients had significantly inferior clinical out-
comes one year after treatment compared to the patients who were 
treated in the most destructed lobes according to the QCT-analysis [7]. 
As emphysematous destruction and distribution are important for 
patient selection and treatment outcome of the coil treatment, we were 
interested in the level of interobserver agreement of visual CT analysis in 
these CT outcomes and whether QCT has additional value. Therefore, 
our aims were to investigate the level of agreement among expert re-
viewers of CT scans in patients with emphysema (and potential coil 
candidates) and the comparison between these expert reviewers and 
QCT software. 
2. Material and methods 
2.1. Study population and study design 
We included patients in this analysis who were treated with coils in 
the intervention arm in the RENEW-study and completed the 12 month 
follow up period and had an evaluable baseline CT scan [6]. In the 
RENEW trial all the ethics committees of the participating hospitals 
approved the study and all patients provided informed consent. Four 
experienced pulmonologists (GC,FS,PS and DS) and one experienced 
chest radiologist (WM) involved in the RENEW-study conducted a visual 
assessment of the baseline CT scans. The CT-assessors only reviewed the 
baseline CT scans and were not informed about patient characteristics, 
treatment lobes or treatment outcome. 
2.2. CT evaluation parameters and QCT-parameter 
All patients underwent a full inspiration (TLC) and full expiration 
(RV) chest CT-scan according the standardized RENEW study scan 
protocol. Non-contrast scans were acquired at 120 kV, with effective 
tube current of 80–100 mA s depending on patient size. For lung eval-
uation, images were reconstructed at 1 mm, with kernel B40f. 
The following characteristics on the CT were scored: the most des-
tructed lobe (left upper versus left lower lobe and right upper versus 
right lower lobe (right middle lobe was not included because no coils are 
placed in this lobe)), emphysema severity of the target lobe (using a 0− 3 
Likert scale, 0 = no emphysema to 3= severe emphysema), heteroge-
neity score of the left and right lung (0= homogeneous to 3= very 
heterogeneous), presence of bronchial wall thickening, presence of 
bronchiectasis (both present versus not-present) and predicted clinical 
outcome (0= no response to 3= massive response). The QCT-analysis 
was performed using LungQ software (Thirona, Nijmegen, The 
Netherlands). The most destructed lobe according to the QCT-analysis 
was based on lobar percentage emphysema which was calculated as 
percentage of low attenuation areas below -950 Hounsfield units on 
inspiratory scans. 
2.3. Other outcome parameters 
Other outcome parameters which were measured at baseline and 
1 year follow up were Residual Volume (RV) measured by body pleth-
ysmography, Forced Expiratory volume in 1 s (FEV1) by spirometry 
(both according to the European Respiratory Society/ American 
Thoracic Society (ATS) guidelines [8,9]), 6-min walk distance(6MWD) 
measured by a 6MWD-test (according to the ATS guidelines [10]) and 
quality of life measured by the St. George’s respiratory questionnaire 
(SGRQ total score) [11]. Furthermore, target lobe volume reduction 
(TLVR) was measured on the CT scan that was repeated 1 year after 
treatment. 
2.4. Statistical analyses 
Statistical analyses were performed with IBM SPSS statistics version 
23 (IBM, Armonk, USA) or Minitab version 19 (Pennsylvania, USA). P- 
values below 0.05 were considered statistically significant. To establish 
the agreement for categorical variables between CT-assessors a Cohen’s 
Kappa was calculated in case of 2 CT-assessors and a Fleiss Kappa in case 
of more than 2 CT-assessors. For continuous variables an intraclass 
correlation (ICC) coefficient was calculated. The level of agreement was 
interpreted as follows: poor ƙ<0, slight 0 < ƙ<0.2, fair 0.21 < ƙ<0.4, 
moderate 0.41 < ƙ<0.6, substantial 0.61 < ƙ<0.8 and almost perfect 
0.81 < ƙ<1.0. [12] For the comparison between QCT and the five 
CT-assessors we used the consensus of the assessors, which was the lobe 
that was most frequently chosen as most destructed by the 5 assessors. 
Furthermore, a Pearson correlation coefficient was calculated to inves-
tigate whether there was an association between the predicted clinical 
outcome based on the CT-scan by the CT-assessors and the change after 
one year in the following clinical outcomes: FEV1, RV, 6MWD, SGRQ 
and TLVR. 
3. Results 
Baseline CT-scans of 134 patients (47 %male, mean FEV1: 26 %pred, 
RV 244 %pred, 6MWD:318 m, SGRQ: 59 units) were rated by all 5 ex-
perts (patient and CT characteristics can be found in Table 1 and a 
flowchart of patient selection in Fig. 1). Table 2 shows the agreement 
between the 5 CT-assessors in the different CT-scan characteristics. In 61 
% of the patients all 5 CT-assessors agreed with the most destructed lobe 
of the left lung, in 20 % 4 CT-assessors were in agreement and in 19 % 3 
CT-assessors were in agreement (Fleiss Kappa: 0.459). For the right lung 
this was 60 %, 24 % and 16 % respectively (Fleiss Kappa: 0.370). There 
was a moderate interobserver agreement between the 5 CT-assessors in 
left target lobe severity (ICC: 0.519) and right target lobe severity 
(ICC:0.561) and a fair agreement in left and right lung heterogeneity 
score (ICC: 0.394 and 0.414 respectively), presence of bronchiectasis 
(Fleiss Kappa: 0.254) and predicted clinical outcome (0.398). Further-
more, there was a poor agreement in the presence of bronchial wall 
thickening (Fleiss Kappa: − 0.127). The consensus of the 5 assessors were 
in agreement with QCT about which was the most destructed lobe in the 
left lung for 77 % of the patients (Cohen’s Kappa: 0.425) and for the 
right lung in 82 % of the patients (Cohen’s Kappa: 0.524) (Tables 2 and 
3). Fig. 2 shows 2 examples of one CT-image with no agreement between 
the 5 assessors and one with complete agreement. There was a signifi-
cant association between the overall predicted clinical outcome at 
baseline and change in FEV1 (r: 0.271, p:0.002) and change in RV 
(− 0.275, p:0.001) and TLVR (− 0.343, p < 0.001) but not with change in 
6MWD or SGRQ total score (Table 4). 
4. Discussion 
Accurate lung HRCT assessment is of great importance in patient 
evaluation for lung volume reduction techniques. Our results show that 
the interobserver agreement between five expert CT-assessors was only 
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fair to moderate when evaluating the most destructed lobe, target lobe 
destruction severity, presence of bronchiectasis and heterogeneity 
within the lung and only poor for the presence of bronchial wall thick-
ening. When combining the mean consensus of the CT-assessors with 
QCT, the number of patients of which there was an agreement on what 
was the most destructed lobe increased. 
The interobserver agreement between CT-assessors about which is 
the most destructed lobe was only fair to moderate. All 5 reviewers 
agreed on the most destructed lobe in approximately 60 % of the pa-
tients and the highest agreement between 2 reviewers was 80 %, 
demonstrating a large interobserver variability. Our post-hoc efficacy 
analysis of the RENEW study showed that it is crucial to treat the most 
emphysematous destructed lobe [7]. The choice of the most destructed 
lobe will probably be more difficult in more homogeneous distributed 
emphysema. Which is in line with that the patients of which the 
CT-assessors did not agree on did have a more homogeneous distribution 
of the emphysema which could attribute to this (left lung: 16.4 % het-
erogeneity difference vs 8.6 % and right lung 16.6 % vs 8.8 %, both 
p < 0.05). However, also the interobserver agreement on the heteroge-
neity score of the lung between CT-assessors was fair. 
Our results show that when combining the consensus of CT-review 
by experts with QCT that the agreement of which was the most des-
tructed lung lobe increased (left lung 61 %–77 % and right lung 60 %–82 
%). Suggesting the additional value of QCT and multiple CT-reviewers, 
especially for a treatment like the coil treatment when lobar target se-
lection is important for treatment outcome. Especially when no clear 
target lobe can be identified, addition of QCT could be helpful. Of 
course, it is not feasible to review every CT by 5 individuals but probably 
2 reviewers could already be useful to obtain a higher yield. The CT- 
assessors in this study were experts in the field of bronchoscopic lung 
volume reduction treatments, so probably the use of QCT would be even 
more important with less experienced CT-reviewers. The published 
protocol of the ELEVATE trial, a randomized controlled trial investi-
gating the coil treatment [13], shows that the trial will include QCT for 
the selection of the most destructed lobe besides a panel of two respi-
ratory physicians and two radiologist. 
In the past, for the visual review of fissure completeness also fair to 
moderate agreements were found between highly experienced pulmo-
nologists and radiologists [14]. QCT-software was developed which was 
found to be comparable to expert radiologist review [15]. Currently, 
QCT is part of the patient selection for the bronchoscopic lung volume 
reduction treatment using endobronchial valves. However, also for this 
purpose QCT is proposed as supportive tool on top of the visual review 
and not as standalone tool [15]. 
Besides the evaluation of the level of destruction and heterogeneity 
of destruction on CT scan, for the coil treatment it is also important to 
assess the type of emphysema, as severe panlobular emphysema, giant 
bullae and paraseptal emphysema are not suitable emphysema patterns 
for treatment [5]. And also the absence of airway disease as this was 
found to be a predictor of response [7]. We only scored the presence of 
bronchial wall thickening and found that the agreement was poor. The 
other visual CT features were not scored systematically in this analysis. 
However, Barr et al. did investigate the interobserver agreement be-
tween a large group of radiologists and pulmonologist of these visual CT 
features in COPD patients and controls [16]. They found a moderate 
agreement (ƙ range: 0.41− 0.6) for absence or presence of emphysema 
Table 1 
Patient characteristics (n = 134).  
Gender, male (%)  63 (47 %) 
Race White 127 (95 %)  
Black or african american 6 (5 %)  
Other 1 (0.7 %) 
Age, years  63 ± 8.0 
FEV1, %predicted  25.7 ± 6.3 
RV, %predicted  244 ± 38 
DLCO, %predicted  34.6 ± 10.6 
6MWD, meter  318 ± 80 
SGRQ, total score  59.4 ± 12.4 
mMRC, score  2.87 ± 0.73 
Treated lobes Upper lobes 102 (76 %)  
Lower lobes 15 (11 %)  
1 upper en 1 lower lobe 14 (10 %  
Right upper lobe only 3 (2 %) 
Consensus assessors* most destructed lobe 
Left lung Upper lobe /Lower lobe 82 %/18 % 
Right lung Upper lobe /Lower lobe 85 %/15 % 
Quantitative CT outcomes  
Left lung- most destructed lobe Upper lobe /Lower lobe 65 %/35 % 
Right lung- most destructed lobe Upper lobe /Lower lobe 65 %/35 % 
Left lung- heterogeneity (absolute)  10.7 % (0.13− 56.7) 
Right lung- heterogeneity (absolute)  10.4 % (0.06− 61.6) 
Data are presented as number (%), mean ± standard deviation or median 
(range). 
FEV1: Forced expiratory volume in 1 s, RV: residual volume, DLCO: diffusing 
capacity for carbon monoxide, 6MWD: 6-min walk distance, SGRQ: St. George’s 
respiratory questionnaire, mMRC: modified medical research council dyspnea 
scale. 
‘Consensus assessors’ was the lobe that was most frequented chosen as most 
destructed by the 5 assessors. 
Fig. 1. Flowchart of patient selection.  
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and presence of panlobular emphysema and a fair agreement (ƙ range: 
0.21− 0.4) for centrilobular emphysema, paraseptal emphysema, bulla 
and bronchial wall thickening [16]. As these are also fair to moderate 
agreements probably it would be helpful if visual CT-analysis could be 
combined with QCT for these features as well. Quantitative software is 
developed to quantify bronchial wall thickening [17] and also deep 
learning techniques to classify different emphysema patters [18], which 
both could be useful. Nambu et al., even concluded that in the assess-
ment of the degree of airway disease in COPD, QCT might even be su-
perior to visual assessment [19]. Furthermore, these CT-features are not 
only relevant for the coil treatment but for other bronchoscopic treat-
ments as well. 
The interobserver agreement between the CT-assessors in the pre-
diction of clinical outcome was fair, which is not surprising as we believe 
it would be difficult to predict clinical response from the CT-scan alone. 
However, it was an interesting finding that the overall prediction was 
associated with an improvement in FEV1, RV and decrease in target 
lobar volume on CT-scan and not with exercise capacity or quality of life. 
So, the prediction was more suitable for more physical outcomes directly 
related to the lung volume reduction effect and less for outcomes that 
are also influenced by other factors. Which is in line with another post- 
hoc analysis of the RENEW-study [20], were we found that for example 
the improvement in exercise capacity and quality of life also was 
affected by the presence of cardiac disease. 
A strength of our analysis is that 5 expert CT-assessors who specif-
ically have a lot of experience in assessing CT-scans of patients with 
severe emphysema and who are potential candidates for a lung volume 
reduction treatment were included. Furthermore, each CT-assessor 
assessed 134 CT scans, which is a large number for this kind of anal-
ysis. A limitation was the scoring of the presence of bronchial wall 
thickening and presence of bronchiectasis, which was only scored as 
present or not present. As the severity of both characteristics is much 
more clinically relevant than present or not present, changing this would 
have provided more useful information. Furthermore, it would have 
been useful if also the type of emphysema (like panlobular emphysema, 
presence of giant bullae and paraseptal emphysema) and the presence of 
airway disease were scored systematically, for example with use of the 
phenotypes defined by the Fleischner society [21]. 
In conclusion, we found a large variability between visual CT 
assessment among a group of expert CT-reviewers. Because some CT- 
features are associated with treatment outcomes and important for pa-
tient selection of bronchoscopic lung volume reduction treatment, we 
advise in case of doubt to include more than one CT-reviewer and to use 
QCT as a supportive tool, which both can be perfectly done in a multi- 
disciplinary team setting [22]. Furthermore, the development of QCT 
software that could provide information on emphysema type and pres-
ence of airway diseases would be very useful. 
Funding 
This research did not receive any specific grant for this analysis from 
funding agencies in the public, commercial, or not-for-profit sectors. 
CRediT authorship contribution statement 
Jorine E. Hartman: Conceptualization, Formal analysis, Investiga-
tion, Methodology, Project administration, Visualization, Writing - 
original draft. Gerard J. Criner: Conceptualization, Data curation, 
Investigation, Methodology, Writing - review & editing. William H. 
Moore: Conceptualization, Data curation, Investigation, Methodology, 
Writing - review & editing. Eva M. van Rikxoort: Data curation, Formal 
analysis, Investigation, Methodology, Software, Writing - review & 
Table 2 
Agreement in CT-scan characteristics between the 5 assessors.   
n (%) Agreement 
Most destructed lobe   
Left lung  0.459* 
All 5 assessors in agreement 66 (61 %)  
1 assessor in disagreement 22 (20 %)  
2 assessors in disagreement 21 (19 %)  
Consensus assessors vs QCT 101 (77 %) 0.425¶ 
Right lung  0.370* 
All 5 assessors in agreement 64 (60 %)  
1 assessor in disagreement 26 (24 %)  
2 assessors in disagreement 17 (16 %)  
Consensus assessors vs QCT 106 (82 %) 0.524¶ 
Target lobe emphysema severity (0¡3)   
Left target lobe  0.519Δ 
Right target lobe  0.561Δ 
Heterogeneity score (0¡3)   
Left lung  0.394Δ 
Right lung  0.414Δ 
Presence of bronchial wall thickening?   
All 5 assessors in agreement-not present 3 (2 %) − 0.127* 
According to 1 assessor present 74 (55 %)  
According to 2 assessors present 44 (33 %)  
According to 3 assessors present 12 (9 %)  
According to 4 assessors present 1 (1 %)  
All 5 assessors in agreement- present 0 (0 %)  
Presence of bronchiectasis?   
All 5 assessors in agreement-not present 93 (69 %) 0.254* 
According to 1 assessor present 27 (20 %)  
According to 2 assessors present 7 (5 %)  
According to 3 assessors present 3 (2 %)  
According to 4 assessors present 3 (2 %)  
All 5 assessors in agreement- present 1 (1 %)  
Clinical outcome (0¡3)  0.389Δ 
Data are presented as number (%) and level of agreement measured by *=Fleiss 
kappa, ¶=Cohen’s kappa or Δ=intraclass coefficient (ICC). Not all assessors 
assessed all CT-scan parameters, therefore the numbers differ. 
Scoring: Target lobe emphysema severity (0− 3): 0 = none, 1=mild, 
2=moderate, 3=severe. Heterogeneity score 0− 3; 0=homogeneous, 
3=heterogeneous. Clinical outcome (0− 3): 0= no response/don’t treat, 1= mild 
response, 2= moderate response, 3= massive response. 
‘Consensus assessors’ was the lobe that was most frequented chosen as most 
destructed by the 5 assessors. QCT = quantitative computed tomography 
analysis. 
Table 3 
Agreement in most destructed lung lobe between 2 assessors or between 1 assessor and QCT.   
Rater 1 Rater 2 Rater 3 Rater 4 Rater 5  
Left lung Right lung Left lung Right lung Left lung Right lung Left lung Right lung Left lung Right lung  
Agreement Agreement Agreement Agreement Agreement Agreement Agreement Agreement Agreement Agreement 
Rater 1   0.310 (69 %) 0.301 (70 %) 0.399 (73 %) 0.320 (70 %) 0.433 (75 %) 0.326 (73 %) 0.495 (77 %) 0.370 (73 %) 
Rater 2     0.504 (87 %) 0.417 (85 %) 0.442 (84 %) 0.490 (89 %) 0.475 (85 %) 0.340 (83 %) 
Rater 3       0.415 (82 %) 0.240 (80 %) 0.521 (86 %) 0.424 (83 %) 
Rater 4         0.644 (89 %) 0.386 (85 %) 
QCT 0.517 (77 %) 0.518 (78 %) 0.370 (75 %) 0.394 (77 %) 0.420 (76 %) 0.512 (81 %) 0.391 (75 %) 0.244 (72 %) 0.508 (80 %) 0.499 (80 %) 
Data are presented as Cohen’s kappa (percentage of scans that were in agreement). 
QCT: quantitative computed tomography analyses. 
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Fig. 2. Examples of an CT-image of which there was no or complete agreement of which was the most destructed lobe. 
A&B&C) Example of CT-image and QCT analysis in which there was not complete agreement: 3 assessors identified the left lower lobe as most destructed and 2 the 
left upper lobe. 
D&E&F) Example of CT-image and QCT analysis in which there was complete agreement: all 5 assessors identified the left upper lobe as most destructed. 
Percentage shown in the right panels are the percentage of low attenuation areas below -950 Hounsfield units on inspiratory scans measured by quantitative 
CT analysis. 
Table 4 
Association between predicted clinical outcome based on baseline CT-scan and change in clinical outcomes 1 year after treatment.   
Δ FEV1 Δ RV Δ 6MWD Δ SGRQtotalscore TLVR  
r p-value r p-value r p-value r p-value r p-value 
Rater 1 0.246 0.004 ¡0.194 0.025 0.161 0.063 − 0.134 0.122 ¡0.271 0.002 
Rater 2 0.221 0.010 ¡0.316 <0.001 0.016 0.856 − 0.119 0.170 − 0.104 0.244 
Rater 3 0.024 0.786 − 0.117 0.183 0.065 0.461 − 0.016 0.857 ¡0.184 0.042 
Rater 4 0.178 0.042 ¡0.203 0.020 0.068 0.436 − 0.047 0.591 ¡0.348 <0.001 
Rater 5 0.271 0.002 ¡0.180 0.037 0.125 0.150 − 0.087 0.317 ¡0.275 0.002 
Average opinion 0.271 0.002 ¡0.275 0.001 0.122 0.159 − 0.105 0.227 ¡0.343 <0.001 
Data are presented as r: Pearson’s correlation coefficient and p-value. Values in bold were statistically significant (p < 0.05). 
Δ= change between baseline and 1 year after coil treatment, FEV1: forced expiratory volume in 1 s, RV: residual volume, 6MWD: 6-min walk distance, SGRQ: St. 
George’s respiratory questionnaire, TLVR: target lobe volume reduction on expiratory CT scan. 
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